People: Achillion Pharmaceuticals Inc (ACHN.O)

ACHN.O on Nasdaq

29 Jan 2015
Change (% chg)

$0.41 (+2.77%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Search Stocks

Graves, Kurt 

Brief Biography

Mr. Kurt C. Graves has been appointed as Independent Director of Achillion Pharmaceuticals, Inc., with effect from June 11, 2012. Mr. Graves has served as Executive Chairman and Chief Executive Officer of Intarcia Therapeutics, a biotechnology company, since September 2010 and has been an independent consultant since October 2009. Prior to joining Intarcia Therapeutics, Mr. Graves served as Executive Vice President, Chief Commercial Officer and Head of Corporate and Strategic Development at Vertex Pharmaceuticals, a pharmaceutical company, from July 2007 to November 2009. From January 1999 to July 2007, Mr. Graves held various positions at Novartis, a pharmaceutical company, most recently as Global Head of the General Medicines Business Unit and Chief Marketing Officer for the Pharmaceuticals division. Prior to Novartis, Mr. Graves held commercial and general management positions of increasing responsibility at Merck and Astra Merck Pharmaceuticals. Mr. Graves currently serves as Chairman of the Board of Intarcia Therapeutics and Radius Therapeutics, a biotechnology company, and is a member of the Board of Directors of Pulmatrix, a biotechnology company. Mr. Graves earned his B.S. in Biology from Hillsdale College and has attended executive leadership programs at Harvard, Wharton School of Management and University of Michigan.

Basic Compensation

Total Annual Compensation, Long-Term Incentive Plans, All Other, Fiscal Year Total,
-- -- -- --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

David Scheer


Milind Deshpande


Mary Kay Fenton


Gautam Shah


David Apelian


Joseph Truitt

As Of 30 Dec 2013
Search Stocks